Menu visibility control

Video

Events

Startup Surgery

Most Recent

Tech City Voices

Making gender pay gap reporting work for tech

News

Top tech stats: UK FinTech, Brexit, cybersecurity and more

News

Startup Weekly: Just Eat’s FoodTech cohort, TrueStart’s call for applications and much more

Press Releases

Redbox Digital Gains Prestigious Magento Global Elite Partner Status
More than £1m transacted using Loot in its first 4 months
HT2 Labs receives Series A investment from City & Guilds Group

Oxford BioTherapeutics secures $10m from Silicon Valley Bank

Medical Lab
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Oxford BioTherapeutics has secured a $10m capital term loan from Silicon Valley Bank to accelerate the expansion of its research and development efforts.

OBT is an international clinical stage biotechnology company focused on developing innovative antibody based therapeutics, including antibody-drug conjugates, to treat cancer and other diseases.

OBT uses the optimal combination of technologies in ADC development through its collaborations with leading companies in the field and its novel OGAP target discovery system – one of the largest of its kind in the world – to provide a unique range of validated, novel antigen targets.

Forget Silicon Valley, Europe’s tech clusters can be stronger together

Christian Rohlff, CEO of Oxford BioTherapeutics, said: “This additional financial support will enable Oxford BioTherapeutics to accelerate the development of our medicines.

“With a long history of supporting life science businesses, Silicon Valley Bank is a valuable partner that recognises Oxford BioTherapeutics’ ability to transform the treatment of cancer and other diseases in an innovative way.”

Nooman Haque, director of UK life sciences and healthcare for Silicon Valley Bank, added: “Silicon Valley Bank is working alongside leading UK life science businesses, like Oxford BioTherapeutics, to provide financial solutions that support this sector’s ambitions to bring innovative therapies to the market.

“This financing demonstrates Silicon Valley Bank’s unique ability to work with businesses like Oxford BioTherapeutics by complementing their equity financing to provide an efficient solution to help stimulate their growth.”

The financing will provide $10m in capital, with $5m being funded immediately. The debt will complement new equity the company is raising.

Enter your email address to receive updates straight to your inbox

* indicates required
Send me news on...
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Editor's picks

gender pay reporting

Making gender pay gap reporting work for tech
posted 7 hours ago

tech stats

Top tech stats: UK FinTech, Brexit, cybersecurity and more
posted on April 22, 2017

startup weekly

Startup Weekly: Just Eat’s FoodTech cohort, TrueStart’s call for applications and much more
posted on April 21, 2017

Divido EP winner

Meet our FinTech Startup of the Year: Divido
posted on April 21, 2017

shanghai

GP Bullhound: UK’s ranking in FinTech declines slightly as China takes the lead
posted on April 21, 2017

TWIT 21.04

Nauta Capital’s $100m raise, Cera’s £1.4m Seed top up, Appear Here’s US expansion and more in the Week in Tech
posted on April 21, 2017